Jun 11, 2019Aratana Therapeutics Granted FDA Approval of NOCITA® (bupivacaine liposome injectable suspension) 10 mL VialCommercial availability of NOCITA 10 mL vial size anticipated by fall 2019
Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, today announced the U.S. Food...
Jun 7, 2019Stockholders Elect All Class III Directors and Approve Proposals
Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, today announced the voting...
May 8, 2019Continued revenue growth across portfolio of marketed pet therapeutics
Aratana recorded $7.4 million in total revenues for the first quarter of 2019, including $2.5 million in NOCITA net product sales, $1.5 million in ENTYCE net product sales and $3.4 million in licensing and collaboration revenue from Elanco for GALLIPRANT.
May 7, 2019
The Company plans on presenting at the Stifel Dental & Veterinary Conference on Wednesday, May 29, 2019 at 8:00 a.m. ET in New York City.
Apr 26, 2019Elanco announces formation of commercial team dedicated to veterinary specialty business
The Company announced it has signed an agreement to be acquired by Elanco Animal Health (NYSE: ELAN), its global collaboration partner on GALLIPRANT® (grapiprant tablets). In conjunction with the transaction, Elanco also announced the formation of a commercial team dedicated to the veterinary specialty business. If the proposed agreement is consummated, the Aratana field force would transition into this commercial team.